HUN was up 1.675 to $10.95 in after-hours trading. Cramer considered Keryx Biopharmaceutical (NASDAQ: KERX) to …
Rigrodsky & Long, P.A. reminds shareholders of Keryx Biopharmaceuticals, Inc. (“Keryx” or the “Company”) …
The stock price of Keryx Biopharmaceuticals (NASDAQ:KERX) jumped by more than 90 percent to around $6.50 a share as of this writing after the company announced the successful results from the long-term Phase 3 study of its …
We issued an updated research report on Keryx Biopharmaceuticals, Inc. KERX on Sep 26, 2017 ... Will You Make a Fortune on the Shift to Electric Cars? Here's another stock idea to consider. Much like petroleum 150 years ago, …
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) announced that its New Drug Application (NDA) for Zerenex has been accepted for filing by the U.S. FDA. The acceptance for filing of the NDA indicates the determination by the FDA that …
The average 12-month price target is $6.30, marking a 58% potential upside from where the stock last closed. Keryx Biopharmaceuticals (NASDAQ:KERX) fell -0.64% in pre ... It does not represent the opinion of Benzinga and has not …
More from The Tell. Must be lonely being a bear these days. Faber took a more traditional tack when he used the Greek stock market’s rally to support the time-tested axiom: “So you need to buy stocks when there’s no reason to buy them …
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) reports a Q4 loss of $0.08 per share vs. consensus for $0.13 loss. Revenues were $327K vs. $530.00K consensus. Michael S. Weiss, Chairman/CEO, said, "During the later part of 2008, …